Epizyme Inc - ESG Rating & Company Profile powered by AI
The page contains a Q&A table on Epizyme Inc. The page displays a zero-cost Sustainability report covering Epizyme Inc. This SDG score for Epizyme Inc represents its reporting of the United Nations SDGs.
Epizyme Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 2.1; made up of an environmental score of 0.0, social score of 1.6 and governance score of 4.8.
2.1
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1551 | Voyager Life PLC | 2.2 | Medium |
| 1551 | Source Natural Foods and Herbal Supplements Ltd | 2.2 | Medium |
| 1571 | Epizyme Inc | 2.1 | Medium |
| 1571 | Cerevel Therapeutics Holdings Inc | 2.1 | Medium |
| 1571 | Charlotte's Web Holdings Inc | 2.1 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Epizyme Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Epizyme Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Epizyme Inc report the average age of the workforce?
Sign up for free to unlockDoes Epizyme Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Epizyme Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Epizyme Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Epizyme Inc offer flexible work?
Sign up for free to unlockDoes Epizyme Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Epizyme Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Epizyme Inc conduct supply chain audits?
Sign up for free to unlockDoes Epizyme Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Epizyme Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Epizyme Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Epizyme Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Epizyme Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Epizyme Inc disclose water use targets?
Sign up for free to unlockDoes Epizyme Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Epizyme Inc have a product recall in the last two years?
Sign up for free to unlockDoes Epizyme Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Epizyme Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Epizyme Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Epizyme Inc disclose parental leave metrics?
Sign up for free to unlockDoes Epizyme Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Epizyme Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Epizyme Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Epizyme Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Epizyme Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Epizyme Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Epizyme Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Epizyme Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Epizyme Inc disclose its waste policy?
Sign up for free to unlockDoes Epizyme Inc report according to TCFD requirements?
Sign up for free to unlockDoes Epizyme Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Epizyme Inc disclose energy use targets?
Sign up for free to unlockDoes Epizyme Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Epizyme Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Epizyme Inc
These potential risks are based on the size, segment and geographies of the company.
Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. As of August 11, 2022, Epizyme, Inc. operates as a subsidiary of Ipsen Biopharmaceuticals, Inc..